DMAC DiaMedica Therapeutics Inc.

4.26
+0.07  (+2%)
Previous Close 4.19
Open 4.13
Price To Book 5.26
Market Cap 51,143,280
Shares 11,956,874
Volume 21,579
Short Ratio
Av. Daily Volume 49,611
Stock charts supplied by TradingView

NewsSee all news

  1. DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease (CKD). This

  2. DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

    Phase II Study of DM199 in Chronic Kidney Disease Commences Screening REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment Management Team Strengthens with Sydney Gilman, Ph.D., Vice

  3. DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that its third quarter 2019 financial results will be released after the markets close on Wednesday, November 13th. DiaMedica will host a live conference call on

  4. DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will meet with institutional investors at the 10th Annual Craig-Hallum Alpha Select Conference on

  5. DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD).

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrolment has completed - noted November 2019.
DM199 - Remedy
Acute ischaemic stroke
Phase 2 initiation announced December 17, 2019 with interim analysis 1Q 2020.
DM199
Chronic Kidney Disease (African Americans)
Phase 2 trial planned.
DM199
Lupus

Latest News

  1. DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease (CKD). This

  2. DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

    Phase II Study of DM199 in Chronic Kidney Disease Commences Screening REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment Management Team Strengthens with Sydney Gilman, Ph.D., Vice

  3. DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that its third quarter 2019 financial results will be released after the markets close on Wednesday, November 13th. DiaMedica will host a live conference call on

  4. DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will meet with institutional investors at the 10th Annual Craig-Hallum Alpha Select Conference on

  5. DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD).

  6. DiaMedica Therapeutics to Present at Lake Street's 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019

    MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth (BIG3) Conference on

  7. DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference

    MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis,